[1]
|
Xu, Y., Wang, L., He, J., et al. (2013) Prevalence and Control of Diabetes in Chinese Adults. JAMA, 310, 948-959.
https://doi.org/10.1001/jama.2013.168118
|
[2]
|
Czik, T., Sobota, I., Slugan, I., Jambrek, B., Pavicic-Astalos, J. (2006) Causes of Blindness in 25% of the Blind Population in Croatia and the Possibilities of Prevention. Acta medica Croatica, 60, 159-161.
|
[3]
|
董宁, 汤欣, 肖林, 等. 房水中多种细胞因子与2型糖尿病患者白内障术后黄斑水肿的关系[J]. 中华实验眼科杂志, 2015, 33(4): 356-361.
|
[4]
|
李红伟, 王晋峰, 王春芳. 非甾体类消炎药预防糖尿病患者白内障术后黄斑水肿的临床观察[J]. 中华临床医师杂志(电子版), 2016, 10(9): 1345-1348.
|
[5]
|
郭媛, 张杰, 张春刚. 2型糖尿病患者行白内障手术后黄斑水肿状况研究[J]. 中华临床医师杂志(电子版), 2015, 9(14): 2662-2664.
|
[6]
|
Medić, A., Jukić, T., Matas, A., Vukojević, K., Sapunar, A. and Znaor, L. (2017) Effect of Preopera-tive Topical Diclofenac on Intraocular Interleukin-12 Concentration and Macular Edema after Cataract Surgery in Patients with Diabetic Retinopathy: A Randomized Controlled Trial. Croatian Medical Journal, 58, 49-55.
https://doi.org/10.3325/cmj.2017.58.49
|
[7]
|
王丹丹, 冯一帆, 廉恒丽, 等. 非甾体类抗炎药不同给药方式对微切口白内障术后黄斑厚度的影响[J]. 中华眼视光学与视觉科学杂志, 2015, 17(8): 488-492.
|
[8]
|
李超, 李斌, 郑波涛, 等. 糖尿病黄斑水肿患者白内障术中玻璃体腔注射曲安奈德的临床观察[J]. 中国眼耳鼻喉科杂志, 2015, 15(1): 32-35.
|
[9]
|
张红言, 朱思泉. 普拉洛芬滴眼液预防白内障术后黄斑囊样水肿的临床研究[J]. 国际眼科杂志, 2008, 8(7): 1370-1372.
|
[10]
|
Tsaousis, K.T., Panagiotou, D.Z., Kostopoulou, E., Vlatsios, V., Stam-pouli, D. (2016) Corneal Oedema after Phacoemulsification in the Early Postoperative Period: A Qualitative Comparative Case-Control Study between Diabetics and Non Diabetics. Annals of Medicine Surgery, 5, 67-71. https://doi.org/10.1016/j.amsu.2015.12.047
|
[11]
|
丁国龙, 谢安明, 雷剑琴, 丁国鹏, 胡亚光. 增生型糖尿病视网膜病变患者玻璃体内注射贝伐单抗后房水中细胞因子的变化及其相关性分析[J]. 眼科新进展, 2017, 37(4): 358-361.
|
[12]
|
Kim, S.J., Flach, A.J., Jampol, L.M., et al. (2010) Nonsteroidal Anti-Inflammatory Drugs in Ophthal-mology. Survey of Ophthalmology, 55, 108-133.
|
[13]
|
Litvin, T.V., Ozawa, G.Y., Bresnick, G.H., et al. (2014) Utility of Hard Exudates for the Screening of Macular Edema. Optometry and Vision Science, 91, 370-375. https://doi.org/10.1097/OPX.0000000000000205
|
[14]
|
褚俏梅, 李方都, 张树芬, 唐琴, 陆艳. 糖尿病性白内障房水中细胞因子IGF-1、bFGF和IL-6的含量测定[J]. 眼科新进展, 2010, 30(6): 531-533.
|
[15]
|
Gverović Antunica, A., Karaman, K., Znaor, L., Sapunar, A., Busko, V. and Puzovic, V. (2012) IL-12 Concentrations in the Aqueous Humor and Serum of Diabetic Retinopathy Patients. Graefe’s Archive for Clinical and Experimental Ophthalmology, 250, 815-821. https://doi.org/10.1007/s00417-011-1905-4
|
[16]
|
宋蔚, 赵帅, 任百超, 郅瑛. 2型糖尿病患者白内障术后黄斑水肿与房水中TGF-β2、FGF及MCP-1的研究[J]. 临床眼科杂志, 2016, 24(5): 385-387.
|
[17]
|
Deepak, K.S. and Sivaswamy, J. (2012) Automatic Assessment of Macular Edema From Color Retinal Images. IEEE Trans Med Imaging, 31, 766-776. https://doi.org/10.1109/TMI.2011.2178856
|
[18]
|
李佳佳, 陈彬川, 帖红艳, 等. 白内障超声乳化吸出联合人工晶状体植入术高危因素临床分析[J]. 眼科新进展, 2014, 34(5): 448-450.
|
[19]
|
Ghosh, S., Roy, I., Biswas, P.N., et al. (2010) Prospective Randomized Comparative Study of Macular Thickness Following Phacoemulsification and Manual Small Incision Cataract Surgery. Acta Ophthalmologica, 88, 102-106.
https://doi.org/10.1111/j.1755-3768.2010.01896.x
|
[20]
|
Lobo, C. (2012) Pseudophakic Cystoid Macular Edema. Ophthalmologica, 227, 61-67.
https://doi.org/10.1159/000331277
|
[21]
|
林为华, 卢敏, 唐浩英, 曾昭荣. 雷珠单抗在糖尿病性白内障治疗中的临床应用[J]. 国际眼科杂志, 2015, 5(15): 880-882.
|
[22]
|
Fong, A.H. and Lai, T.Y. (2013) Long-Term Effectiveness of Ranibizumab for Agerelated Macular Degeneration and Diabetic Macular Edema. Clinical Interventions in Aging, 8, 467-483.
|
[23]
|
Donnenfeld, E.D., Nichamin, L.D., Hardten, D.R., Raizman, M.B., Trattler, W., Rajpal, R.K., et al. (2011) Twice-Daily, Preservative-Free Ketorolac 0.45% for Treatment of Inflammation and Pain after Cataract Surgery. American Journal of Ophthalmology, 151, 420-426.
|
[24]
|
Greenberg, P.B., Tseng, V.L., Wu, W.C., et al. (2011) Prevalence and Predictors of Ocular Complications Associated with Cataract Surgery in United States Veterans. Ophthalmology, 118, 507-514.
|
[25]
|
McCafferty, S., Harris, A., Kew, C., Kassm, T., Lane, L., Levine, J. and Raven, M. (2017) Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Study with Adjunctive Once Daily Topical Nepafenac 0.3% versus Placebo. BMC Ophthalmology, 17, 16. https://doi.org/10.1186/s12886-017-0405-7
|
[26]
|
Almeida, D., Khan, Z., Xing, L., Bakar, S., Rahim, K., Urton, T. and El-Defrawy, S. (2012) Prophylacticnepafenac and Ketorolac versus Placebo in Preventing Postoperative Macula-redema after Uneventful Phacoemulsification. Journal of Cataract & Refractive Surgery, 38, 1537-1543.
|
[27]
|
Walters, T., Raizman, M., Ernest, P., Gayton, J. and Lehmann, R. (2007) In Vivo Pharmacokinetics and in Vitro Pharmacody-namics of Nepafenac, Amfenac, Ketorolac, and Bromfenac. Journal of Cataract & Refractive Surgery, 33, 1539-1545.
|
[28]
|
Kern, T.S., Miller, C.M., Du, Y., Zheng, L., Mohr, S., Ball, S.L., Kim, M., Jamison, J.A. and Binga-man, D.P. (2007) Topical Administration of Nepafenac Inhibits Diabetes-Induced Retinal Microvascular Disease and Underlying Abnormalities of Retinal Metabolism and Physiology. Diabetes, 56, 373-379. https://doi.org/10.2337/db05-1621
|
[29]
|
Heier, J.S., Awh, C.C., Busbee, B.G., Waterbury, L.D., Daniel, P., Stoller, G.L. and Cleary, T.S. (2009) Vitreous Nonsteroidal Antiinflammatory Drug Concentrations and Prostaglandin E2 Levels in Vitrectomy Patients Treated with Ketorolac 0.4%, Bromfenac 0.09%, and Nepafenac 0.1%. Retina, 29, 1310-1313.
https://doi.org/10.1097/IAE.0b013e3181b094e6
|